Showing results (571-580 of 2,338) with videos related to

Sort By:
Pageof 234
Clinical Lung Cancer|January 20, 2021
Decreased Overall Survival in HIV-associated Non-small-cell Lung CancerKristen Hysell, Ramsey Yusuf, Lydia Barakat, et al.
Clinical Lung Cancer|January 22, 2021
Ninety-Day Mortality: Redefining the Perioperative Period After Lung ResectionMarcus Taylor, Stuart W Grant, Doug West, et al.
Clinical Lung Cancer|January 17, 2022
Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 PandemicL B M Hijmering-Kappelle, T J N Hiltermann, F Bensch
Clinical Lung Cancer|January 17, 2022
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50Liran Holtzman, Mor Moskovitz, Damien Urban, et al.
Clinical Lung Cancer|January 20, 2022
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung CancerLihong Zhang, Xia Yang, Zongjuan Ming, et al.
Clinical Lung Cancer|January 19, 2022
Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung CancerMarleen E Logtenberg, Ben Tomlow, Elisabeth A Kastelijn, et al.
Clinical Lung Cancer|January 7, 2022
A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health CentersAamna Akhtar, Ernesto Sosa, Samuel Castro, et al.
Clinical Lung Cancer|December 10, 2021
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, et al.
Clinical Lung Cancer|April 17, 2017
Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung CancerEleshia J Morrison, Paul J Novotny, Jeff A Sloan, et al.
Clinical Lung Cancer|March 22, 2021
Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USAEdward S Kim, Jonathan K Kish, Agnieszka Cseh, et al.
Pageof 234